A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib
Abstract The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administe...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.493 |
| _version_ | 1797740012762038272 |
|---|---|
| author | Jorge J. Castillo Shayna Sarosiek Catherine A. Flynn Carly Leventoff Megan Little Timothy White Kirsten Meid Steven P. Treon |
| author_facet | Jorge J. Castillo Shayna Sarosiek Catherine A. Flynn Carly Leventoff Megan Little Timothy White Kirsten Meid Steven P. Treon |
| author_sort | Jorge J. Castillo |
| collection | DOAJ |
| description | Abstract The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administered at 100 mg by mouth once daily in four‐week cycles for up to 24 cycles. This study was registered under ClinicalTrials.Gov ID NCT04115059. Three participants were enrolled and received at least one cycle of dasatinib. The best response was stable disease. Two patients received 5 months and one patient received 1 month of therapy. The dose of dasatinib was decreased in one participant due to volume overload. Based on the lack of responses observed, the study was terminated. Dasatinib might not be effective in patients with WM progressing on ibrutinib. |
| first_indexed | 2024-03-12T14:06:27Z |
| format | Article |
| id | doaj.art-2b3ae86ac79d4f00af7997d2bc26306a |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-12T14:06:27Z |
| publishDate | 2022-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-2b3ae86ac79d4f00af7997d2bc26306a2023-08-21T14:06:34ZengWileyeJHaem2688-61462022-08-013392792910.1002/jha2.493A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinibJorge J. Castillo0Shayna Sarosiek1Catherine A. Flynn2Carly Leventoff3Megan Little4Timothy White5Kirsten Meid6Steven P. Treon7Bing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts USABing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts USABing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts USABing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts USABing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts USABing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts USABing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts USABing Center for Waldenström Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts USAAbstract The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administered at 100 mg by mouth once daily in four‐week cycles for up to 24 cycles. This study was registered under ClinicalTrials.Gov ID NCT04115059. Three participants were enrolled and received at least one cycle of dasatinib. The best response was stable disease. Two patients received 5 months and one patient received 1 month of therapy. The dose of dasatinib was decreased in one participant due to volume overload. Based on the lack of responses observed, the study was terminated. Dasatinib might not be effective in patients with WM progressing on ibrutinib.https://doi.org/10.1002/jha2.493clinical trialdasatinibHCKWaldenström macroglobulinemia |
| spellingShingle | Jorge J. Castillo Shayna Sarosiek Catherine A. Flynn Carly Leventoff Megan Little Timothy White Kirsten Meid Steven P. Treon A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib eJHaem clinical trial dasatinib HCK Waldenström macroglobulinemia |
| title | A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib |
| title_full | A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib |
| title_fullStr | A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib |
| title_full_unstemmed | A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib |
| title_short | A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib |
| title_sort | pilot study on dasatinib in patients with waldenstrom macroglobulinemia progressing on ibrutinib |
| topic | clinical trial dasatinib HCK Waldenström macroglobulinemia |
| url | https://doi.org/10.1002/jha2.493 |
| work_keys_str_mv | AT jorgejcastillo apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT shaynasarosiek apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT catherineaflynn apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT carlyleventoff apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT meganlittle apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT timothywhite apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT kirstenmeid apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT stevenptreon apilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT jorgejcastillo pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT shaynasarosiek pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT catherineaflynn pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT carlyleventoff pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT meganlittle pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT timothywhite pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT kirstenmeid pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib AT stevenptreon pilotstudyondasatinibinpatientswithwaldenstrommacroglobulinemiaprogressingonibrutinib |